©IDOSR PUBLICATIONS International Digital Organization for Scientific Research

IDOSR JOURNAL OF SCIENTIFIC RESEARCH 11(2):18-22, 2026. ISSN: 2550-794X

https://doi.org/10.59298/IDOSRJSR/2026/11.2.1822 IDOSRJSR11106

Lipid Nanoparticle Delivery Systems for Antiretroviral Therapy Optimization in HIV-Positive Pregnant Women

Abaho Areeba Fortunate

Department of Pharmacy Kampala International University Uganda
Email address: fortunate.abaho@studwc.kiu.ac.ug

ABSTRACT

Human immunodeficiency virus infection in pregnancy remained a significant global health concern, particularly in low- and middle-income countries where vertical transmission continued to contribute substantially to pediatric HIV incidence. Despite advances in combination antiretroviral therapy, physiological alterations during pregnancy complicated drug pharmacokinetics, reduced therapeutic predictability, and may increase maternal or fetal toxicity. Lipid nanoparticle delivery systems emerged as transformative platforms in modern drug delivery, offering improved bioavailability, targeted tissue distribution, and controlled release kinetics. The purpose of this review is to critically examine the potential of lipid nanoparticle-based antiretroviral formulations to optimize therapeutic outcomes in HIV positive pregnant women. This article was developed through a comprehensive narrative synthesis of contemporary literature in nanomedicine, maternal pharmacology, and HIV therapeutics. Available evidence indicated that lipid nanoparticles can enhance intracellular drug delivery, stabilize labile compounds, reduce systemic exposure, and potentially modulate placental transfer while maintaining viral suppression. Furthermore, long-acting nanoformulations may improve adherence and reduce dosing frequency, a crucial determinant of maternal and fetal protection. Lipid nanoparticle systems represent a promising strategy to reconcile efficacy, safety, and adherence challenges in maternal HIV management, warranting carefully designed translational and clinical investigations.

Keywords: Lipid nanoparticles, Antiretroviral therapy, HIV in pregnancy, Maternal pharmacokinetics, Nanomedicine.

INTRODUCTION

Human immunodeficiency virus continues to impose a considerable burden on maternal and child health worldwide. According to the World Health Organization and UNAIDS, millions of women of reproductive age live with HIV, and without adequate intervention, vertical transmission during pregnancy, delivery, or breastfeeding remains a persistent threat [1, 2]. Combination antiretroviral therapy has dramatically reduced maternal morbidity and mother-to-child transmission [3]; however, pregnancy introduces profound physiological alterations that complicate drug disposition and therapeutic predictability [4].

Pregnancy is characterized by expanded plasma volume, altered hepatic enzyme activity, increased renal clearance, and dynamic placental transport mechanisms [4]. These changes can lower plasma drug concentrations, compromise viral suppression, and necessitate dose adjustments that may inadvertently increase toxicity. Furthermore, certain antiretroviral agents exhibit suboptimal placental transfer, whereas others cross extensively, raising concerns regarding fetal exposure and long-term developmental safety [5]. Adherence challenges, pill burden, gastrointestinal intolerance, and stigma further complicate sustained viral suppression.

Lipid nanoparticle technology, demonstrated at global scale in advanced therapeutic platforms developed by organizations such as Moderna and Pfizer, has transformed drug delivery science by enabling enhanced stability, cellular uptake, and targeted distribution of bioactive molecules [6]. These systems offer the potential to overcome pharmacokinetic variability, reduce systemic toxicity, and provide sustained release formulations tailored to the unique physiological context of pregnancy. This review critically evaluates the biochemical, pharmacological, safety, and translational dimensions of lipid nanoparticle delivery systems in optimizing antiretroviral therapy among HIV

positive pregnant women. The subsequent sections examine pathophysiological considerations in pregnancy, mechanistic foundations of lipid nanoparticles, pharmacological advantages, regulatory and ethical considerations, and future translational directions.

Pathophysiological and Pharmacokinetic Considerations of HIV in Pregnancy

Pregnancy induces complex immunological and metabolic adaptations necessary to support fetal development while maintaining maternal homeostasis. These adaptations significantly influence HIV pathogenesis and antiretroviral pharmacokinetics. Maternal immune tolerance, characterized by modulation of T cell responses and cytokine profiles, may alter viral dynamics and immune activation patterns [7]. Although effective therapy suppresses viral replication, physiological changes can influence drug exposure.

Hemodilution secondary to plasma volume expansion reduces peak plasma concentrations of several antiretroviral agents [8]. Increased cardiac output and altered protein binding further influence drug distribution. Enhanced renal blood flow and glomerular filtration accelerate clearance of renally eliminated drugs, while hormonal modulation of cytochrome P450 enzymes alters hepatic metabolism. Collectively, these changes may lead to subtherapeutic drug levels, risking viral rebound and resistance.

The placenta constitutes a critical pharmacological interface. Its syncytiotrophoblast layer expresses efflux transporters such as P-glycoprotein and breast cancer resistance protein, which limit fetal exposure to xenobiotics [9]. However, transporter expression varies across gestation, introducing temporal variability in fetal drug exposure. Some antiretroviral agents cross the placenta efficiently, providing fetal prophylaxis, whereas others demonstrate limited transfer, potentially reducing protective efficacy.

Additionally, gastrointestinal intolerance common in pregnancy can impair oral drug absorption. Pill burden and daily dosing requirements may compromise adherence, particularly in resource-constrained settings. Thus, optimizing antiretroviral therapy during pregnancy requires strategies that stabilize systemic drug concentrations, minimize toxicity, and sustain viral suppression despite physiological variability [10]. Lipid nanoparticle delivery systems offer a mechanistically rational approach to address these challenges by modifying drug distribution, protecting labile compounds, and potentially enabling long-acting formulations less susceptible to pregnancy-related pharmacokinetic fluctuations [11].

Lipid Nanoparticle Systems: Biochemical Composition and Mechanistic Foundations

Lipid nanoparticles are submicron colloidal carriers composed of biocompatible lipid constituents that self-assemble into structured delivery vehicles [12]. Their architecture typically includes ionizable or cationic lipids, phospholipids, cholesterol, and polyethylene glycol conjugated lipids [13]. Each component fulfills a distinct biochemical function. Ionizable lipids facilitate encapsulation of charged therapeutic agents and promote endosomal escape through pH-dependent membrane destabilization [14]. Phospholipids contribute structural integrity, while cholesterol enhances membrane fluidity and stability. Polyethylene glycol conjugated lipids reduce aggregation, prolong systemic circulation, and modulate biodistribution by limiting opsonization.

Drug incorporation may occur through passive entrapment, electrostatic complexation, or lipid solubilization depending on the physicochemical properties of the antiretroviral compound. Hydrophobic drugs integrate within lipid bilayers, whereas hydrophilic agents may be encapsulated in aqueous cores [15]. Controlled release kinetics can be engineered by adjusting lipid composition, particle size, and surface characteristics. Upon systemic administration, lipid nanoparticles interact with plasma proteins, forming a biomolecular corona that influences cellular uptake. Endocytosis, mediated by clathrin-dependent or caveolae pathways, enables intracellular delivery. Acidification within endosomes triggers ionizable lipid protonation, destabilizing endosomal membranes and releasing therapeutic cargo into the cytosol [16].

From a biophysical perspective, particle size and surface charge critically determine tissue distribution and placental transport potential. Nanoparticles within specific size ranges may limit passive diffusion across the placental barrier, thereby modulating fetal exposure [17]. Moreover, surface modification with targeting ligands offers theoretical capacity for preferential uptake by maternal immune cells harboring viral reservoirs. Thus, lipid nanoparticle systems represent versatile platforms capable of tailoring pharmacokinetics and intracellular trafficking of antiretroviral agents in ways unattainable with conventional oral formulations.

Pharmacological Advantages of Lipid Nanoparticles in Antiretroviral Optimization

The pharmacological advantages of lipid nanoparticle-based antiretroviral formulations derive from their capacity to reshape drug disposition and enhance therapeutic indices [18]. Improved bioavailability is achieved through protection of encapsulated drugs from enzymatic degradation and first-pass metabolism. By facilitating lymphatic uptake and sustained systemic release, nanoparticles may maintain plasma concentrations within therapeutic windows despite pregnancy-induced metabolic shifts. Targeted tissue distribution constitutes another critical advantage. Macrophages and lymphoid tissues serve as viral reservoirs, and nanoparticle systems can enhance drug accumulation within these compartments [19]. This targeted delivery may contribute to deeper viral suppression and reduced risk of resistance development.

Controlled release properties enable long-acting formulations that reduce dosing frequency from daily to monthly or longer intervals. Such regimens may substantially improve adherence, particularly in settings where access to healthcare is inconsistent. Reduced pill burden also mitigates gastrointestinal intolerance and stigma associated with visible medication use. Importantly, lipid nanoparticles may decrease systemic toxicity by limiting peak plasma concentrations and off-target tissue exposure [20]. Encapsulation can reduce mitochondrial toxicity and metabolic complications associated with certain antiretroviral agents. Furthermore, by modulating particle size and surface characteristics, it may be possible to limit transplacental passage while preserving maternal efficacy, thereby optimizing the balance between fetal protection and safety.

Sustained intracellular concentrations achieved through nanoparticle-mediated delivery may also overcome pharmacokinetic variability during pregnancy. Rather than relying on fluctuating plasma levels, therapeutic efficacy may depend on maintained intracellular drug reservoirs, providing resilience against physiological changes. Collectively, these pharmacological attributes position lipid nanoparticles as promising tools for refining maternal antiretroviral therapy beyond the constraints of conventional oral dosing.

Safety, Ethical, and Regulatory Considerations in Pregnant Populations

Despite their promise, lipid nanoparticle systems must undergo rigorous safety evaluation before clinical integration in pregnant populations. Teratogenicity risk assessment requires detailed reproductive toxicology studies in appropriate animal models, with attention to gestational timing, dose-response relationships, and long-term offspring outcomes. Placental biodistribution studies are essential to determine nanoparticle accumulation patterns [21]. While limited placental transfer may reduce fetal exposure, unintended accumulation within placental tissue could disrupt nutrient exchange or trigger inflammatory responses. Immunogenicity represents another concern, as certain lipid components may activate complement pathways or induce cytokine release.

Regulatory pathways for maternal therapeutics remain complex. Pregnant women have historically been excluded from early-phase clinical trials, resulting in delayed safety data acquisition [22]. Ethical imperatives now emphasize the inclusion of pregnant populations under carefully controlled conditions to ensure evidence-based care rather than extrapolation from nonpregnant adults. Risk-benefit analyses must consider the substantial morbidity associated with untreated maternal HIV. In this context, innovative delivery systems that enhance viral suppression while minimizing toxicity align with ethical principles of beneficence and justice. Transparent informed consent processes and community engagement are crucial in clinical evaluation of nanomedicine platforms. Furthermore, manufacturing consistency, scalability, and cost-effectiveness must be addressed to ensure equitable global access. Regulatory agencies require robust characterization of particle size distribution, stability, and reproducibility to maintain quality standards. While lipid nanoparticles offer substantial therapeutic potential, their translation into maternal HIV care demands meticulous safety validation and ethically grounded clinical investigation.

Current Evidence, Clinical Translation, and Future Directions

Preclinical investigations have demonstrated enhanced antiretroviral bioavailability and sustained release using lipid-based nanoformulations. Long-acting injectable systems incorporating integrase inhibitors and protease inhibitors have shown prolonged viral suppression in animal models [23, 24]. These findings suggest feasibility for reducing dosing frequency during pregnancy while maintaining maternal viral control.

Emerging translational research explores combination nanoparticle platforms capable of co-delivering multiple antiretroviral agents, thereby preserving the principles of combination therapy within a single formulation. Personalized nanomedicine approaches, informed by pharmacogenomic profiling, may further optimize dosing strategies in diverse populations.

Future investigations must clarify the interaction between nanoparticle systems and placental transporters across gestation. Advanced imaging and ex vivo placental perfusion models can elucidate biodistribution patterns [25]. Clinical trials specifically designed for pregnant populations are essential to establish safety, efficacy, and optimal dosing intervals.

Integration of lipid nanoparticle-based therapies into global maternal HIV programs requires collaboration between pharmaceutical scientists, obstetricians, infectious disease specialists, and public health authorities. Cost considerations and manufacturing scalability will influence accessibility in regions with the highest HIV prevalence [26]. As nanotechnology continues to evolve, rational design of lipid components with enhanced biodegradability and minimal immunogenicity will further refine therapeutic indices. The convergence of nanomedicine and maternal pharmacology holds potential to transform prevention of vertical transmission and improve long-term maternal health outcomes.

CONCLUSION

Optimization of antiretroviral therapy in HIV positive pregnant women demands strategies that reconcile physiological variability, safety considerations, adherence challenges, and sustained viral suppression. Pregnancy alters drug pharmacokinetics in ways that complicate conventional dosing regimens, while placental dynamics introduce uncertainty regarding fetal exposure. Lipid nanoparticle delivery systems offer a scientifically robust platform capable of enhancing bioavailability, stabilizing plasma concentrations, targeting viral reservoirs, and

enabling long-acting formulations that may substantially improve adherence. Their modular design permits tailoring of biodistribution and release kinetics, providing opportunities to minimize systemic toxicity and potentially regulate placental transfer. Nevertheless, translation into maternal clinical practice requires comprehensive toxicological evaluation, ethical inclusion of pregnant women in trials, and stringent regulatory oversight. Continued interdisciplinary research integrating nanotechnology, pharmacology, and maternal medicine will be essential to realize the full therapeutic potential of these systems. Carefully designed, pregnancy-specific clinical trials evaluating lipid nanoparticle-based antiretroviral formulations should be prioritized to establish safety, efficacy, and optimal integration into global maternal HIV treatment guidelines.

REFERENCES

1. Mother-to-child transmission of HIV, https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/mother-to-child-transmission-of-hiv
2. Obeagu, E., P.C., U., Simeon, E., Uti, D., Ukaidi, C., Echegu, A.: Confronting Dual Challenges: Substance Abuse and HIV/AIDS. 2, 1–8 (2024)
3. Alum, E.U., Uti, D.E., Ugwu, O.P.-C., Alum, B.N.: Toward a cure - Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review. Medicine (Baltimore). 103, e38768 (2024). https://doi.org/10.1097/MD.0000000000038768
4. Kazma, J.M., van den Anker, J., Allegaert, K., Dallmann, A., Ahmadzia, H.K.: Anatomical and physiological alterations of pregnancy. J Pharmacokinet Pharmacodyn. 47, 271–285 (2020). https://doi.org/10.1007/s10928-020-09677-1
5. Fleşeriu, T., Meliţ, L.E., Mărginean, C.O., Pop, A.V., Văsieşiu, A.-M.: Maternal HIV Infection and Antiretroviral Therapy in Pregnancy: Implications for Vertical Transmission, Fetal Safety, and Long-Term Infant Outcomes. Pathogens. 14, (2025). https://doi.org/10.3390/pathogens14080818
6. Scioli Montoto, S., Muraca, G., Ruiz, M.E.: Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects. Front. Mol. Biosci. 7, (2020). https://doi.org/10.3389/fmolb.2020.587997
7. Yang, F., Zheng, Q., Jin, L.: Dynamic Function and Composition Changes of Immune Cells During Normal and Pathological Pregnancy at the Maternal-Fetal Interface. Front. Immunol. 10, (2019). https://doi.org/10.3389/fimmu.2019.02317
8. Pope Jr, R., Kashuba, A.: Darunavir for use in pregnant women with HIV. Expert Review of Clinical Pharmacology. 10, 1317–1327 (2017). https://doi.org/10.1080/17512433.2017.1390428
9. Kotta-Loizou, I., Pritsa, A., Antasouras, G., Vasilopoulos, S.N., Voulgaridou, G., Papadopoulou, S.K., Coutts, R.H.A., Lechouritis, E., Giaginis, C.: Fetus Exposure to Drugs and Chemicals: A Holistic Overview on the Assessment of Their Transport and Metabolism across the Human Placental Barrier. Diseases. 12, (2024). https://doi.org/10.3390/diseases12060114
10. Samson, A.O., Adepoju, A.O., Amusa, M.O.: Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine. 102, e35673 (2023). https://doi.org/10.1097/MD.0000000000035673
11. Harishchandra, V.B.: Nanoparticle-based Drug Delivery Systems: Design Strategies, Formulation Advances, Mechanistic Insights, Clinical Applications, and Translational Challenges. Asian Journal of Research in Medicine and Medical Science. 8, 18–45 (2026). https://doi.org/10.56557/ajrmms/2026/v8i192
12. Subroto, E., Andoyo, R., Indiarto, R.: Solid Lipid Nanoparticles: Review of the Current Research on Encapsulation and Delivery Systems for Active and Antioxidant Compounds. Antioxidants. 12, (2023). https://doi.org/10.3390/antiox12030633
13. Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
14. Lu, Z.-R., Sun, D.: Mechanism of pH-sensitive Amphiphilic Endosomal Escape of Ionizable Lipid Nanoparticles for Cytosolic Nucleic Acid Delivery. Pharm Res. 42, 1065–1077 (2025). https://doi.org/10.1007/s11095-025-03890-8
15. Oliveira, M.S., Goulart, G.C.A., Ferreira, L.A.M., Carneiro, G.: Hydrophobic ion pairing as a strategy to improve drug encapsulation into lipid nanocarriers for the cancer treatment. Expert Opinion on Drug Delivery. 14, 983–995 (2017). https://doi.org/10.1080/17425247.2017.1266329
16. Lu, Z.-R., Sun, D.: Mechanism of pH-sensitive Amphiphilic Endosomal Escape of Ionizable Lipid Nanoparticles for Cytosolic Nucleic Acid Delivery. Pharm Res. 42, 1065–1077 (2025). https://doi.org/10.1007/s11095-025-03890-8
17. Muoth, C., Aengenheister, L., Kucki, M., Wick, P., Buerki-Thurnherr, T.: Nanoparticle Transport Across the Placental Barrier: Pushing the Field Forward! Nanomedicine (Lond.). 11, 941–957 (2016). https://doi.org/10.2217/nnm-2015-0012

18. Suriyarachchi, D.D.C., Katuwavila, N.P.: Lipid nanoparticles in antiretroviral therapy: A nanotechnology breakthrough for HIV/AIDS treatment. HIV Medicine. 26, 658–676 (2025). https://doi.org/10.1111/hiv.13770
19. Herskovitz, J., Gendelman, H.E.: HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication. J Neuroimmune Pharmacol. 14, 52–67 (2019). https://doi.org/10.1007/s11481-018-9785-6
20. Paun, R.A., Jurchuk, S., Tabrizian, M.: A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors. Bioengineering & Translational Medicine. 9, e10601 (2024). https://doi.org/10.1002/btm2.10601
21. Ho, D., Leong, J.W., Crew, R.C., Norret, M., House, M.J., Mark, P.J., Waddell, B.J., Iyer, K.S., Keelan, J.A.: Maternal-placental-fetal biodistribution of multimodal polymeric nanoparticles in a pregnant rat model in mid and late gestation. Sci Rep. 7, 2866 (2017). https://doi.org/10.1038/s41598-017-03128-7
22. Abrams, E.J., Mofenson, L.M., Pozniak, A., Lockman, S., Colbers, A., Belew, Y., Clayden, P., Mirochnick, M., Siberry, G.K., Ford, N., Khoo, S., Renaud, F., Vitoria, M., Venter, W.D.F., Doherty, M., Penazzato, M., Groups, on B. of the P. and C.E.: Enhanced and Timely Investigation of ARVs for Use in Pregnant Women. JAIDS Journal of Acquired Immune Deficiency Syndromes. 86, 607 (2021). https://doi.org/10.1097/QAI.0000000000002597
23. Kovarova, M., Swanson, M.D., Sanchez, R.I., Baker, C.E., Steve, J., Spagnuolo, R.A., Howell, B.J., Hazuda, D.J., Garcia, J.V.: A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges. J Antimicrob Chemother. 71, 1586–1596 (2016). https://doi.org/10.1093/jac/dkw042
24. Labh, R., Gupta, R.: Emerging Trends in the Long-Acting Antiretroviral Therapy: Current Status and Therapeutic Challenges. Current HIV Research. 19, 4–13 (2021). https://doi.org/10.2174/1570162X18666200824104140
25. Ho, D., Leong, J.W., Crew, R.C., Norret, M., House, M.J., Mark, P.J., Waddell, B.J., Iyer, K.S., Keelan, J.A.: Maternal-placental-fetal biodistribution of multimodal polymeric nanoparticles in a pregnant rat model in mid and late gestation. Sci Rep. 7, 2866 (2017). https://doi.org/10.1038/s41598-017-03128-7
26. Ezenwaji, C.O., Alum, E.U., Ugwu, O.P.-C.: Bridging the gap: telemedicine as a solution for HIV care inequities in rural and vulnerable communities. International Journal for Equity in Health. 24, 205 (2025). https://doi.org/10.1186/s12939-025-02584-2

CITE AS: Abaho Areeba Fortunate (2026). Lipid Nanoparticle Delivery Systems for Antiretroviral Therapy Optimization in HIV-Positive Pregnant Women. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 11(2):18-22. https://doi.org/10.59298/IDOSRJSR/2026/11.2.1822